AR041255A1 - Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso. - Google Patents

Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.

Info

Publication number
AR041255A1
AR041255A1 ARP030103331A ARP030103331A AR041255A1 AR 041255 A1 AR041255 A1 AR 041255A1 AR P030103331 A ARP030103331 A AR P030103331A AR P030103331 A ARP030103331 A AR P030103331A AR 041255 A1 AR041255 A1 AR 041255A1
Authority
AR
Argentina
Prior art keywords
alkyl
compound
alkoxy
amino
formula
Prior art date
Application number
ARP030103331A
Other languages
English (en)
Inventor
Ann Marie Madera
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR041255A1 publication Critical patent/AR041255A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente proporciona un compuesto de fórmula (1) o una sal. La presente proporciona composiciones que comprenden, métodos de uso, y métodos para la preparación de un compuesto de fórmula (1) Reivindicación 1: Un compuesto de fórmula (1) o unasal farmacéuticamente aceptables de la misma, en donde: n es 0, 1 ó 2; p es 1 ó 2; R1 es arilo o heteroarilo; R2 es heterociclilo; R3 es hidrógeno, alquilo, o -C(=O)-R5, donde R5 es alquilo, alcoxilo, arilo, o ariloxilo; y cada R4 esindependientemente hidrógeno, hidroxilo, ciano, alquilo, alcoxilo, tioalquilo, tioalquilo, halo, haloalquilo, hidroxialquilo, nitro, alcoxicarbonilo, alquilcarbonilo, alquilsulfonilo, arilsulfonilo, haloalquilsulfonilo, amino, alquilamino,dialquilamino, alquil(aril)amino, alquilaminocarbonilo, alquilcarbonilamino, alquilcarbonil(alquilamino), alquilaminosulfonilo, alquilsulfonilamino o metilenodioxihidrógeno, alquilo, alcoxilo, halo, o haloalquilo.
ARP030103331A 2002-09-17 2003-09-15 Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso. AR041255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41123902P 2002-09-17 2002-09-17

Publications (1)

Publication Number Publication Date
AR041255A1 true AR041255A1 (es) 2005-05-11

Family

ID=32030655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103331A AR041255A1 (es) 2002-09-17 2003-09-15 Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.

Country Status (29)

Country Link
US (1) US7247651B2 (es)
EP (1) EP1587788B9 (es)
JP (1) JP4327091B2 (es)
KR (1) KR100686758B1 (es)
CN (1) CN1314669C (es)
AR (1) AR041255A1 (es)
AT (1) ATE362469T1 (es)
AU (1) AU2003273855B2 (es)
BR (1) BR0314352A (es)
CA (1) CA2496765A1 (es)
DE (1) DE60313895T2 (es)
DK (1) DK1587788T3 (es)
ES (1) ES2287518T3 (es)
GT (1) GT200300199A (es)
HK (1) HK1083500A1 (es)
HR (1) HRP20050229A2 (es)
MX (1) MXPA05002696A (es)
MY (1) MY138826A (es)
NO (1) NO20050666L (es)
NZ (1) NZ537982A (es)
PA (1) PA8582201A1 (es)
PE (1) PE20050054A1 (es)
PL (1) PL376020A1 (es)
PT (1) PT1587788E (es)
RU (1) RU2327685C2 (es)
TW (1) TWI249402B (es)
UY (1) UY27980A1 (es)
WO (1) WO2004026830A1 (es)
ZA (1) ZA200501306B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4455064B2 (ja) 2002-03-27 2010-04-21 グラクソ グループ リミテッド キノリン誘導体および5−ht6リガンドとしてのその使用
CA2533369C (en) 2003-07-22 2009-07-14 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
BRPI0417858B1 (pt) * 2003-12-23 2017-10-10 H. Lundbeck A/S Derivative compounds of aniline and pharmaceutical composition that understand it
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
ES2359725T3 (es) 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
MX2009004898A (es) * 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN103288707B (zh) * 2013-05-28 2015-12-23 浙江大学 一种3-苯巯基吲哚衍生物的制备方法
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 芳香族複素環式化合物及び医薬におけるその応用
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 芳香族ヘテロ環誘導体及びその医薬的適用
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3155008B2 (ja) 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての4−インドール誘導体
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE69903239T2 (de) 1998-06-30 2003-09-11 Lilly Co Eli Auf serotonin-verwandte Systeme wirkende Piperidin-Derivate
FR2788772B1 (fr) * 1999-01-26 2001-03-02 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
RU2294932C2 (ru) * 2001-06-07 2007-03-10 Ф.Хоффманн-Ля Рош Аг Новые производные индола со сродством к рецептору 5-ht6
JP2005501019A (ja) * 2001-06-15 2005-01-13 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6レセプター親和性を有する4−ピペラジニルインドール誘導体
JP2005527463A (ja) * 2001-08-07 2005-09-15 スミスクライン ビーチャム パブリック リミテッド カンパニー Cns疾患を治療するための5−ht6受容体アフィニティーを有する3−アリールスルホニル−7−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
US7943639B2 (en) 2002-06-20 2011-05-17 Proximagen Limited Compounds

Also Published As

Publication number Publication date
CA2496765A1 (en) 2004-04-01
ES2287518T3 (es) 2007-12-16
NZ537982A (en) 2007-05-31
PA8582201A1 (es) 2004-04-23
HRP20050229A2 (hr) 2006-04-30
EP1587788A1 (en) 2005-10-26
HK1083500A1 (en) 2006-07-07
DE60313895T2 (de) 2008-01-17
JP2006503052A (ja) 2006-01-26
GT200300199A (es) 2006-08-22
PE20050054A1 (es) 2005-02-18
US7247651B2 (en) 2007-07-24
KR100686758B1 (ko) 2007-02-26
CN1314669C (zh) 2007-05-09
WO2004026830A1 (en) 2004-04-01
UY27980A1 (es) 2004-03-31
NO20050666L (no) 2005-03-11
DE60313895D1 (de) 2007-06-28
EP1587788B9 (en) 2007-10-24
JP4327091B2 (ja) 2009-09-09
CN1681782A (zh) 2005-10-12
RU2005111587A (ru) 2005-11-20
TWI249402B (en) 2006-02-21
US20040063724A1 (en) 2004-04-01
AU2003273855A1 (en) 2004-04-08
MXPA05002696A (es) 2005-05-05
PT1587788E (pt) 2007-08-20
EP1587788B1 (en) 2007-05-16
PL376020A1 (en) 2005-12-12
TW200410685A (en) 2004-07-01
BR0314352A (pt) 2005-07-19
RU2327685C2 (ru) 2008-06-27
DK1587788T3 (da) 2007-09-24
ATE362469T1 (de) 2007-06-15
AU2003273855B2 (en) 2009-01-15
MY138826A (en) 2009-07-31
KR20050057357A (ko) 2005-06-16
ZA200501306B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
AR041255A1 (es) Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
CR8861A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina
AR041256A1 (es) Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
MXPA04007470A (es) Piridinonas sustituidas.
LU92146I2 (fr) Dasatinib et ses sels pharmaceutiquement acceptables
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
DOP2005000022A (es) "derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina"
ATE284690T1 (de) Antithrombotische diamine
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
BR0012697A (pt) Inibidores da diferenciação de th2
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
ECSP045484A (es) Derivados de carbamato de quinuclidina
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
AR008614A1 (es) UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMI
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling

Legal Events

Date Code Title Description
FB Suspension of granting procedure